Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Jumpei Teramachi, Kazuaki Miyagawa, DDS, PhD, Delgado-Calle Jesus, PhD, Jolene Windle, PhD, Noriyoshi Kurihara, DDS, PhD, G David Roodman, MD PhD

Blood (2019) 134 (Supplement_1): 4336.

https://doi.org/10.1182/blood-2019-126959

Published: 2019

Journal Articles

Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma

Rong Fu, Jr., PhD, Fengjuan Jiang, Hui Liu, Zhaoyun Liu, Siyang Yan, Jin Chen, Zonghong Shao, MD, Qing Shao

Blood (2019) 134 (Supplement_1): 4416.

https://doi.org/10.1182/blood-2019-127022

Published: 2019

Journal Articles

Adiponectin Inhibits the Differentiation and Maturation of Osteoclasts Via mTOR Pathway in Multiple Myeloma

Rong Fu, Jr., PhD, Liu Zhaoyun, Hui Liu, Yanqi Li, Yangyang Wang, Rui Xing, Fu Mi, Zonghong Shao, MD, Jia Song, Chenhuan Xiang

Blood (2019) 134 (Supplement_1): 5521.

https://doi.org/10.1182/blood-2019-126861

Published: 2019

Journal Articles

Myelofibrosis osteoclasts are clonal and functionally impaired

Ivo Veletic, Taghi Manshouri, Asha S. Multani, C. Cameron Yin, Lei Chen, Srdan Verstovsek, Zeev Estrov

Blood (2019) 133 (21): 2320–2324.

https://doi.org/10.1182/blood-2018-10-878926

Published: 2019

Includes: Supplemental data

Journal Articles

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

Jingsong He, MD, Qingxiao Chen, MS, Yang Yang, MD, Yi Li, MD, Li Yang, MD, He Huang, MD PhD, Qing Yi, MD PhD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 5392.

https://doi.org/10.1182/blood.V130.Suppl_1.5392.5392

Published: 2017

Journal Articles

The Exosomes-Derived EGFR Ligand Amphiregulin (AREG) Is a New Pro-Osteoclastogenic Factor in Multiple Myeloma

Emanuela Vicario, PhD, Stefania Raimondo, PhD, Laura Saieva, PhD, Federica Costa, PhD, Vincenza Tinnirello, Fabrizio Accardi, MD, Franco Aversa, MD, Nicola Giuliani, MD PhD, Riccardo Alessandro, PhD

Blood (2017) 130 (Supplement 1): 1776.

https://doi.org/10.1182/blood.V130.Suppl_1.1776.1776

Published: 2017

Journal Articles

A Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma

Noriyoshi Kurihara, DDS, PhD, Yasuhisa Ohata, MD PhD, Gabriel M. Pagnotti, PhD, John Chirgwin, PhD, G David Roodman, MD PhD

Blood (2017) 130 (Supplement 1): 4360.

https://doi.org/10.1182/blood.V130.Suppl_1.4360.4360

Published: 2017

Journal Articles

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

Qingxiao Chen, MS, Jingsong He, MD, Huiyao Gu, Xi Huang, MD, Jing Chen, MD, Zhang En Fan, Xing Guo, MD, Haimeng Yan, He Huang, MD, Zhen Cai, MD PhD

Blood (2017) 130 (Supplement 1): 3079.

https://doi.org/10.1182/blood.V130.Suppl_1.3079.3079

Published: 2017

Journal Articles

Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis

Ivo Veletic, MD, Taghi Manshouri, C. Cameron Yin, MD PhD, Kate J Newberry, PhD, Srdan Verstovsek, MD PhD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 1664.

https://doi.org/10.1182/blood.V130.Suppl_1.1664.1664

Published: 2017

Journal Articles

Multiplex Quantitative Imaging Analysis of Bone-Remodeling Cells in Patients with Myelofibrosis

Ivo Veletic, MD, Taghi Manshouri, PhD, Sanja Prijic, PhD, C. Cameron Yin, MD PhD, Joseph E Bove, IV, BS, Ying Zhang, MD MS, Srdan Verstovsek, MD PhD, Zeev Estrov, MD

Blood (2016) 128 (22): 4280.

https://doi.org/10.1182/blood.V128.22.4280.4280

Published: 2016

Journal Articles

EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability

Juraj Adamik, PhD, Rebecca Silbermann, MD, Konstantinos Lontos, MD, Peng Zhang, PhD, Quanhong Sun, Deborah Lynn Galson, PhD, G. David Roodman, MD PhD

Blood (2016) 128 (22): 3247.

https://doi.org/10.1182/blood.V128.22.3247.3247

Published: 2016

Journal Articles

Netrin-1 and Its Receptors Unc5b and DCC May be Useful Targets for Preventing Multiple Myeloma Bone Lesions

Aránzazu Mediero, Amitabha Mazumder, MD, Bruce Cronstein

Blood (2015) 126 (23): 1815.

https://doi.org/10.1182/blood.V126.23.1815.1815

Published: 2015

Journal Articles

Adaptation of Marrow Osteoblast Morphology Mediated By a Hematopoietic-Derived Endosteal Cell Is Critical for Donor HSC Engraftment after BMT

Kathleen Overholt, MD, Satoru Otsuru, Victoria Best, Adam Guess, Timothy S. Olson, MD PhD, Massimo Dominici, MD, Edwin M. Horwitz, MD PhD

Blood (2015) 126 (23): 3603.

https://doi.org/10.1182/blood.V126.23.3603.3603

Published: 2015

Journal Articles

Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma

Jumpei Teramachi, DDS, PhD, Masahiro Hiasa, PhD DDS, Asuka Oda, Hirofumi Tenshin, DDS, Ryota Amachi, DDS, PhD, Takeshi Harada, MDPhD, Derek Hanson, Keiichiro Watanabe, DDS, PhD, Shiro Fujii, MD, Kumiko Kagawa, MD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Itsuro Endo, MD PhD, Shuji Ozaki, MD PhD, Toshio Matsumoto, MD PhD, Masahiro Abe, MD PhD

Blood (2015) 126 (23): 4203.

https://doi.org/10.1182/blood.V126.23.4203.4203

Published: 2015

Journal Articles

Myeloma Cell-Derived Runx2 Promotes Myeloma Progression and Bone-Homing

Mei Li, PhD, Timothy N Trotter, BS, Deniz Peker, MD, Patrick D Rowan, BS, Pan Qianying, MD, Suva J. Larry, PhD, Amjad Javed, PhD, Yang Yang, MD PhD

Blood (2014) 124 (21): 724.

https://doi.org/10.1182/blood.V124.21.724.724

Published: 2014

Journal Articles

Chemerin As a New Potential Player in the Immunoregulatory Activity of Mesenchymal Stromal Cells

Paola Vinci, PhD, Antonio Bastone, Erica Dander, Annalisa Del Prete, Mario Salmona, Silvano Sozzani, Andrea Biondi, Giovanna D'Amico

Blood (2014) 124 (21): 1590.

https://doi.org/10.1182/blood.V124.21.1590.1590

Published: 2014

Journal Articles

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

Homare Eda, Loredana Santo, Diana D Cirstea, Andrew J Yee, Tyler A Scullen, Neeharika Nemani, Yuko Mishima, Shirin Arastu-Kapur, Erica Evans, Juswinder Singh, Christopher J Kirk, William F Westlin, Noopur S Raje

Blood (2013) 122 (21): 682.

https://doi.org/10.1182/blood.V122.21.682.682

Published: 2013

Journal Articles

Regulation Of Hematopoietic Stem Cell Trafficking By The Coagulation Pathway

Shiri Gur Cohen, MSc, Tomer Itkin, PhD, Orit Kollet, PhD, Sagarika Chakrabarty, PhD, Aya Ludin, DMD, PhD, Karin Golan, MSc, Alexander Kalinkovich, MD, PhD, Xin-Jiang Lu, PhD, Jeff R. Crosby, PhD, Brett P. Monia, PhD, Charles T Esmon, PhD, Wolfram Ruf, MD, Tsvee Lapidot, PhD

Blood (2013) 122 (21): 456.

https://doi.org/10.1182/blood.V122.21.456.456

Published: 2013

Journal Articles

HMOX1 Is a Targeted Therapy for Myeloma-Induced Bone Disease.

Xin Li, PhD, Wen Ling, MS, Sharmin Khan, MS, Sathisha Upparahalli Venkateshaiah, PhD, Rakesh Bam, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD

Blood (2012) 120 (21): 2944.

https://doi.org/10.1182/blood.V120.21.2944.2944

Published: 2012

Journal Articles

Reduced HMOX1 Expression in Myelomatous Bones Is Associated with Poor Survival and Its Induction Regulates Osteoclastogenesis and Osteoblastogenesis

Xin Li, PhD, Qing Zhang, PhD, Sarah K. Johnson, PhD, Wen Ling, MS, Sharmin Khan, MS, Frits van Rhee, MD, PhD, Saad Z Usmani, MD FACP, Sarah Waheed, MD, Bart Barlogie, MD, PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD

Blood (2012) 120 (21): 1815.

https://doi.org/10.1182/blood.V120.21.1815.1815

Published: 2012

NARROW

Pivotal Role of OCL-Derived IGF1 in Drug Resistance and Bone Destruction in MM

Complement C3a Not C4a Activates Osteoclasts By Regulating the PI3K/PDK1/SGK3 Pathway in Patients with Multiple Myeloma

Adiponectin Inhibits the Differentiation and Maturation of Osteoclasts Via mTOR Pathway in Multiple Myeloma

Myelofibrosis osteoclasts are clonal and functionally impaired

The Novel Subtype-Selective Histone Deacetylase (HDAC) Inhibitor, Chidamide, Exerts Dual Anti-Myeloma and Bone Protective Effect in Vitro and In Vivo

The Exosomes-Derived EGFR Ligand Amphiregulin (AREG) Is a New Pro-Osteoclastogenic Factor in Multiple Myeloma

A Novel Ex-Vivo Model of Prolonged Osteoblast Suppression in Multiple Myeloma

The Mechanisms of PIM Kinase Inhibitor, SGI-1776 Free Base, in Treating Myeloma-Associated Bone Disease

Neoplastic Monocyte-Derived Osteoclasts Are Highly Proliferative, but Sub-Functional in MPN-Associated Myelofibrosis

Multiplex Quantitative Imaging Analysis of Bone-Remodeling Cells in Patients with Myelofibrosis

EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability

Netrin-1 and Its Receptors Unc5b and DCC May be Useful Targets for Preventing Multiple Myeloma Bone Lesions

Adaptation of Marrow Osteoblast Morphology Mediated By a Hematopoietic-Derived Endosteal Cell Is Critical for Donor HSC Engraftment after BMT

Pim Inhibition Suppresses Osteoclastogenesis and Tumor Growth in Myeloma

Myeloma Cell-Derived Runx2 Promotes Myeloma Progression and Bone-Homing

Chemerin As a New Potential Player in the Immunoregulatory Activity of Mesenchymal Stromal Cells

A Novel Bruton′s Tyrosine Kinase Inhibitor CC-292 In Combination With The Proteasome Inhibitor Carfilzomib Iimpacts Multiple Myeloma Bone Microenviroment With Resultant Anti-Myeloma Activity

Regulation Of Hematopoietic Stem Cell Trafficking By The Coagulation Pathway

HMOX1 Is a Targeted Therapy for Myeloma-Induced Bone Disease.

Reduced HMOX1 Expression in Myelomatous Bones Is Associated with Poor Survival and Its Induction Regulates Osteoclastogenesis and Osteoblastogenesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only